Psychedelics startups are on a long journey to consumer markets, but these 5 VCs are taking the ride
TechCrunch
MAY 4, 2022
Previously relegated to underground communities and rave culture, drugs like ketamine, MDMA (commonly known as ecstasy) and psilocybin are now being studied to develop therapies to treat everything from PTSD to cluster headaches. We are most excited by drug developers. billion in part due to their cannabinoid portfolios.
Let's personalize your content